- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (7)
20 result(s) found for: Chickenpox.
Displaying page 1 of 1.
EudraCT Number: 2005-005825-75 | Sponsor Protocol Number: 105909 MeMuRu-OKA 047 | Start Date*: 2006-03-20 | |||||||||||
Sponsor Name:GLAXO SMITHKLINE | |||||||||||||
Full Title: A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline s GSK Biologicals measles-mumps-rubella-varicella candidate vaccine MeMuRu-OKA and ... | |||||||||||||
Medical condition: Active immunisation against mumps, measles, rubella and varicella | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002669-19 | Sponsor Protocol Number: X04-VAR-402 | Start Date*: 2004-12-23 | |||||||||||
Sponsor Name:AVENTIS PASTEUR MSD S.P.A. | |||||||||||||
Full Title: A double-blind, randomised, controlled, multi-centre safety study of a refrigerator-stable formulation of VARIVAX® in healthy 12 to 15 month-old infants. | |||||||||||||
Medical condition: Active immunisation against varicella | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000592-27 | Sponsor Protocol Number: 13102014 | Start Date*: 2015-06-18 |
Sponsor Name:Helsinki University Central Hospital | ||
Full Title: Immunodeficiency in cartilage-hair hypoplasia: sub-project on safety of vaccination against chickenpox | ||
Medical condition: Cartilage-hair hypoplasia patients. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001332-22 | Sponsor Protocol Number: RG_12-201 | Start Date*: 2013-06-20 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: PEPtalk 2: Pilot of a randomised controlled trial to compare VZIG and aciclovir as post-exposure prophylaxis against chickenpox in children with cancer | |||||||||||||
Medical condition: Exposure to Varicella by children who have cancer. | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004541-33 | Sponsor Protocol Number: immvzmpr1 | Start Date*: Information not available in EudraCT |
Sponsor Name:Västra Götalandsregionen | ||
Full Title: A clinical study to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer. | ||
Medical condition: This study will be conducted as a longitudinal study. Former studies have shown that immunity is affected after treatment against childhood cancer. We want to investigate humoral and cell-mediated ... | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-006065-14 | Sponsor Protocol Number: 105908 | Start Date*: 2006-04-04 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline's (GSK) Biologicals' measles-mumps-rubella-varicella candidate vaccine (MeMuRu-OKA) and ... | ||
Medical condition: Healthy male and female children between 15 months and 6 years of age who previously received an MMR vaccine will receive one dose of MMR + V or MMRV. A second dose of varicella vaccine will be giv... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001608-37 | Sponsor Protocol Number: 115555MMRV-063 | Start Date*: 2011-12-16 | ||||||||||||||||||||||||||
Sponsor Name:GLAXOSMITHKLINE BIOLOGICALS SA | ||||||||||||||||||||||||||||
Full Title: Open, randomised, controlled, multicenter Phase IIIb study to evaluate the immune response and safety, after the administration of GlaxoSmithKline Biologicals live attenuated measles mumps rubell... | ||||||||||||||||||||||||||||
Medical condition: Vaccination of children from the age of 9 months up to 12 years inclusive against measles, mumps, rubella and varicella diseases | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003535-30 | Sponsor Protocol Number: 200147 | Start Date*: 2015-10-13 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase III, double blind, randomized, comparative study of the safety and immunogenicity of GSK Biologicals’ Varilrix HSA-free varicella vaccine and Varilrix™ given as a 2 dose course in the secon... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Vaccinating Healthy volunteers (Active immunization against varicella virus disease of healthy children in their second year of life). | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) EE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-002676-41 | Sponsor Protocol Number: 100388,103494,104105,104106 | Start Date*: 2005-05-23 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: Blinded, randomised, controlled, multicenter study to evaluate the clinical efficacy against varicella disease of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (Varilrix) given on ... | ||||||||||||||||||||||||||||
Medical condition: Healthy children between 12-22 months (including the day before the 23-month birthday) of age at the time of vaccination with no history of measles, mumps, rubella and varicella diseases/vaccination. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SE (Completed) LT (Completed) SK (Completed) CZ (Completed) IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004442-25 | Sponsor Protocol Number: CFAM810B2304 | Start Date*: 2016-04-12 |
Sponsor Name:Novartis Pharmaceuticals | ||
Full Title: A multicenter, open-label, single-arm, two-step study to evaluate the safety and single-dose pharmacokinetics of famciclovir and multiple-dose safety after administration of famciclovir oral pediat... | ||
Medical condition: Chickenpox Herpes Zoster | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-002529-31 | Sponsor Protocol Number: VZVAC-TX | Start Date*: 2020-08-20 |
Sponsor Name:Oslo University Hospital | ||
Full Title: SAFETY AND EFFICACY OF SHINGRIX VACCINATION IN VARICELLA NAÏVE RENAL TRANSPLANT RECIPIENTS | ||
Medical condition: Kidney transplant recipients who are varicella-zoster sero-negative. The study aim to evaluate if the Shingrix vaccine will produce immune response in varicella naive kidney transplant recipients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001910-21 | Sponsor Protocol Number: 217212 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals SA (GSK) | |||||||||||||
Full Title: A phase II, observer-blind, randomized, controlled study to evaluate the immunogenicity and safety of a varicella vaccine at various potencies compared with Varivax, as a first dose, administered i... | |||||||||||||
Medical condition: Immunogenicity and safety of a varicella vaccine in healthy children | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Ongoing) PL (Ongoing) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005881-38 | Sponsor Protocol Number: 108760 | Start Date*: 2015-06-25 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, randomized, double-blind study of Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine), one lot using new measles and rubella working seeds and one lot using old working see... | ||
Medical condition: Measles, mumps, rubella and varicella diseases | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-005882-19 | Sponsor Protocol Number: 109995 | Start Date*: 2015-06-25 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: Non-inferiority of GSK Biologicals’ measles-mumps-rubella-varicella (MMRV) vaccine 208136 vs Priorix™ and Priorix™ coadministered with Varilrix™ (comparator) and to evaluate non-inferiority of Prio... | ||
Medical condition: Measles, mumps, rubella and varicella diseases | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-001643-79 | Sponsor Protocol Number: SAS115358 | Start Date*: 2012-01-24 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with p... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) LV (Completed) CZ (Completed) LT (Completed) ES (Completed) AT (Completed) SE (Not Authorised) BE (Completed) DK (Completed) NL (Completed) BG (Completed) IT (Completed) FI (Prematurely Ended) SK (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001509-15 | Sponsor Protocol Number: 208109/231 | Start Date*: 2015-06-25 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine (Havrix) [720 El.U/0.5 mL dose] admini... | ||
Medical condition: Active immunization against hepatitis A of healthy children 15 months of age at the time of the first study vaccination. | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-000454-18 | Sponsor Protocol Number: 110058 | Start Date*: 2017-07-10 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase II randomized, observer blind, multicenter study of GlaxoSmithKline (GSK) Biologicals’ combined measles-mumps-rubella-varicella vaccine (MMRV) versus ProQuad, according to a one dose schedu... | ||
Medical condition: Healthy volunteers (Use of the candidate MMRV vaccine for immunization of healthy children 12 - 14 months of age against measles, mumps, rubella and varicella). | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-005860-31 | Sponsor Protocol Number: 111870 | Start Date*: 2015-06-25 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: Immunogenicity of GlaxoSmithKline Biologicals’ MMR vaccine (209762) vs. M-M-R® II, when co-administered with hepatitis A, varicella and pneumococcal conjugate vaccines to children 12-15 months of age | ||
Medical condition: Diseases caused by measles, mumps, rubella and varicella viruses | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2022-000506-10 | Sponsor Protocol Number: APHP211036 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Assistance Publique des Hôpitaux de Paris | |||||||||||||
Full Title: Bariticinib in the treatment of new-onset juvenile dermatomyositis :a phase II trial | |||||||||||||
Medical condition: New-onset juvenile dermatomyositis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000709-10 | Sponsor Protocol Number: UKM12_0026 | Start Date*: 2014-12-19 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.